Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals

Cosman, Felicia; Libanati, Cesar; Deignan, Cynthia; Zhang, Yu; Wang, Zhenxun; Ferrari, Serge; Jensen, Jens‐Erik Beck; Peris, Pilar; Bertoldo, Francesco; Lespessailles, Éric; Hesse, Eric; Cummings, Steven R.

doi:10.1002/jbm4.10546

Cited by 6 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the baseline T-score falls below -2.7 (total hip) and -3 (lumbar spine), alendronate has a <50% probability of achieving a BMD target above the osteoporosis range, whereas these probabilities remain relatively high for regimens starting with ROMO. 16…”

Section: Romo Followed By Antiresorptive Treatment Increases the Like...mentioning

confidence: 99%

Clinical Studies On Romosozumab: An Alternative For Individuals With A High Risk Of Osteoporotic Fractures: A Current Concepts Review (Part II)

Rodriguez-Merchan,

Moreno-Garcia,

De la Corte-Rodriguez

2023

SurgiColl

View full text Add to dashboard Cite

Romosumab (ROMO) should be used to treat postmenopausal women with osteoporosis at high fracture risk after carefully considering the cardiovascular status and the risk/benefit balance. Clinicians should avoid ROMO for patients with a history of myocardial infarction or stroke in the past 12 months. Although ROMO offers an alternative for patients with a high risk of osteoporotic fractures, it is affected by previous osteoporosis treatment: using denosumab (DENO) and oral bisphosphonates for over one year attenuates its effect. An additional 12 months of DENO appears to be more effective than ibandronate for the enhancement of bone mineral density (BMD) as a sequential agent after 12 months of ROMO, with few severe adverse events. However, it is important to emphasize that ROMO is not a first-choice medication. It is only indicated when bisphosphonates cannot help, and its clinical use has demonstrated cardiovascular risks. The cost and availability could also make its use problematic in clinical practice. Therefore, although ROMO represents an important advance in the treatment of osteoporosis, it is by no means a solution for osteoporosis.

show abstract

Section: Romo Followed By Antiresorptive Treatment Increases the Like...mentioning

confidence: 99%